Genmab — August 2024
-
Interessant artikel om CD38 og udmattede T-celler https://www.lumc.nl/en/news/2024/new-solution-found-for-cmv-and-potentially-other-chronic-viruses-and-cancer/
-
@Peter12 det var netop den effekt ved dara, der fik os til at tro, at der var en mulighed i solide. Men dara fejlede og kursen fik mega tæsk. Det er muligt, at anti-CD38 behandling har mange muligheder,
men måske ikke i fremskreden cancer. Tak for linket ! -
Jeg er ikke sikker på det er helt den samme mekanisme. Det nye er at man kan genoplive udmattede T-celler. Den gamle er vist denne beskrivelse https://www.mdanderson.org/publications/cancer-frontline/immunotherapy-fires-up-protein-on-tumors-that-supresses-immune-a.h00-159226512.html
-
Aktier: Fra stejl optur til panik https://proinvestor.com/boards/121648
-
Panik på det hysteriske marked = gode opkøbsmuligheder i den næste tid
-
Hvis tiden er med dig (hvilket den altid bør være ved investeringer generelt), så husk Warren Buffet's motto.
-
Carnegie höjer riktkursen för Genmab till 2 760 danska kronor (2 720), upprepar köp - BN (Finwire)
2024-08-05 08:16 https://www.placera.se/placera/telegram/2024/08/05/genmab-carnegie-hojer-riktkursen-for-genmab-till-2-760-danska-kronor-2-720-upprepar-kop-bn.html -
Genmab Takes Full Control of Acasunlimab Development Program https://www.globenewswire.com/news-release/2024/08/05/2924128/0/en/Genmab-Takes-Full-Control-of-Acasunlimab-Development-Program.html
-
BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update https://www.globenewswire.com/news-release/2024/08/05/2924129/0/en/BioNTech-Announces-Second-Quarter-2024-Financial-Results-and-Corporate-Update.html -mentioning Acasunlimab at ESMO
-
ESMO 24 Abstract Title: A Phase II Safety and Efficacy Study of PM8002/BNT-327 in Combination with Chemotherapy in Patients with EGFR-mutated NSCLC
Mini-oral Presentation : September 14, 2024,
Presentation Number: 1255MOAbstract Title: A Phase Ib/II Study to Assess the Safety and Efficacy of PM8002/BNT327 in Combination with Nab-Paclitaxel for First Line Treatment of Locally Advanced or Metastatic Triple-Negative Breast Cancer
Mini-oral Presentation Date & Time: September 16, 2024 -
"While the emerging clinical profile of BNT311/GEN1046 (acasunlimab) is encouraging, for reasons relating to portfolio strategy, BioNTech opted not to participate in the further development of the program, including a planned Phase 3 trial. BioNTech and Genmab A/S (“Genmab”) will continue their collaboration under the existing agreements which was expanded in 2022."
-
Det koster på kursen - fra 1882 til 1837!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind